摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl-7-amino-5-(3-nitrphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carboxylate

中文名称
——
中文别名
——
英文名称
ethyl-7-amino-5-(3-nitrphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carboxylate
英文别名
Ethyl 7-amino-5-(3-nitrophenyl)-2,4-dioxo-1,5-dihydropyrano[2,3-d]pyrimidine-6-carboxylate
ethyl-7-amino-5-(3-nitrphenyl)-2,4-dioxo-2,3,4,5-tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carboxylate化学式
CAS
——
化学式
C16H14N4O7
mdl
——
分子量
374.31
InChiKey
KVKKZOIDTBGQIA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    166
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

  • 作为产物:
    参考文献:
    名称:
    吡喃并[2,3-d]嘧啶-2,4-二酮和吡啶并[2,3-d]嘧啶-2,4,6,8-丁酮的合成:评价抗肿瘤活性
    摘要:
    一系列的一些新颖吡喃并[2,3-的d ]嘧啶4 - 10以75-95%的产率和吡啶并[2,3- d ]嘧啶衍生物11 - 16报道用75-92%的产率。建筑结构是由5芳基巴比妥酸2与活性亲核体碳或氮反应(例如巴比妥酸和乙酰丙酮)或双嘧啶-2,4,6-三酮衍生物3的回流而实现的。与环化试剂,如五氧化二磷,水合肼和氨基噻唑。在光谱分析的基础上阐明了新合成的结构。筛选了一些选定的成员的抗肿瘤活性。在这些筛选的化合物9,16,7,10和8显示出高的抗肿瘤活性。
    DOI:
    10.1002/jhet.3830
点击查看最新优质反应信息

文献信息

  • 4-(4-Propylpiperazine-1-yl)butane-1-sulfonic acid-modified silica-coated magnetic nanoparticles: A novel and recyclable catalyst for the synthesis of 5-arylidinebarbituric acids and pyrano[2,3-<i>d</i>]pyrimidinedione derivatives in aqueous media
    作者:M. Pourghasemi-Lati、F. Shirini、M. Alinia-Asli、M.A. Rezvani
    DOI:10.1002/aoc.4605
    日期:2018.12
    A mild, simple and efficient procedure for the preparation of barbituric acid and pyrano[2,3‐d]pyrimidine derivatives in aqueous media is described using 4‐(4‐propylpiperazine‐1‐yl)butane‐1‐sulfonic acid‐modified silica‐coated magnetic nanoparticles as a novel and reusable catalyst. The catalyst was easily isolated from the reaction mixture by magnetic decantation using an external magnet and reused
    使用4-(4-丙基哌嗪-1-基)丁烷-1-磺酸改性的二氧化硅描述了一种温和,简单,有效的方法来制备介质中的巴比妥酸喃并[2,3- d ]嘧啶生物包覆的磁性纳米颗粒可作为新型可重复使用的催化剂。通过使用外部磁体的磁倾析,可以容易地从反应混合物中分离出催化剂,并且在不显着降低活性的情况下重复使用至少八次。
  • Efficient biogenesis of Cu2O nanoparticles using extract of Camellia sinensis leaf: Evaluation of catalytic, cytotoxicity, antioxidant, and anti-human ovarian cancer properties
    作者:Lei Dou、Xinxin Zhang、Mohammad Mahdi Zangeneh、Yi Zhang
    DOI:10.1016/j.bioorg.2020.104468
    日期:2021.1
    and synthesized in aqueous medium using Camellia sinensis leaf extract. The as-prepared Cu2O nanoparticles was thoroughly characterized using XRD, FT-IR, FESEM, EDX, TEM and X-ray elemental mapping techniques. The as-synthesized Cu2O/C. sinensis NPs applied as novel nanocatalyst for the synthesis of annulated fused pyrano[2,3-d]pyrimidinones via a one-pot, three-component condensation of a barbituric
    目前,属纳米粒子尤其是纳米粒子被用于治疗不同的疾病,例如肿瘤和癌症。近年来,许多化学治疗补充剂已由纳米颗粒配制而成。在本研究中,使用山茶花叶提取物性介质中制备和合成了纳米颗粒。使用 XRD、FT-IR、FESEM、EDX、TEM 和 X 射线元素映射技术对所制备的 Cu 2 O 纳米粒子进行了彻底表征。合成的Cu 2 O/ C. sinensisNPs 作为新型纳米催化剂,通过巴比妥酸、芳香醛和丙二腈乙酸乙酯在 25 o C温和条件下的一锅三组分缩合反应合成环状稠合喃并 [2,3-d] 嘧啶酮。这种简便方法的主要特性是包括简单的后处理程序、避免危险或污染化学品、温和条件下的显着收率和一锅反应。我们评估了这些纳米颗粒对 Caov-3、SW-626 和 SK-OV-3 细胞系的抗人卵巢癌潜力。用于研究 CuCl 2 ⋅2H 2 O, C. sinensis的抗氧化活性和
  • Nickel NPs @N-doped titania: an efficient and recyclable heterogeneous nanocatalytic system for one-pot synthesis of pyrano[2,3-d]pyrimidines and 1,8-dioxo-octahydroxanthenes
    作者:Yogayta Rajinder、Monika Gupta、Jaspreet Kour
    DOI:10.1007/s13738-019-01669-4
    日期:2019.9
    form and imparts it unique catalytic properties. In the present work, we report the application of heterogeneous nickel nanoparticles in the synthesis of some biologically important heterocyclic compounds. In brief, we doped titania nanostructures with nitrogen and then used them as a support material for immobilizing nickel nanoparticles onto them. The nanoparticles of nickel were prepared by the chemical
    摘要催化在化学工业中占有非常重要和有希望的位置。在典型的化学转化中,催化剂的使用减少了基于试剂的废物并提高了反应选择性,从而最大程度地减少了获得任何副产物的机会。近年来,在催化领域中纳米技术的引入进一步改变了它。它具有极小的尺寸,形状和非常大的表面积/体积比,将纳米催化剂与普通的本体形式区分开,并赋予其独特的催化性能。在目前的工作中,我们报告了异质纳米颗粒在一些生物学上重要的杂环化合物的合成中的应用。简单来说,我们用氮掺杂了二氧化钛纳米结构,然后将它们用作将纳米颗粒固定在其上的载体材料。通过乙酸化学还原制备的纳米颗粒。如此制备的催化剂,即负载在氮掺杂的二氧化钛上的纳米颗粒(NPs @然后研究了N掺杂的TiO 2)对喃并[2,3- d ]嘧啶和1,8-二氧-八氢氧杂蒽的催化活性。通过SEM-EDX分析研究了催化剂的表面和元素组成。进行了TEM分析以研究内部形态和所形成的纳米结
查看更多

同类化合物

叔-丁基2-(甲磺酰)-5,7-二氢螺[吡喃并[4,3-D]嘧啶并-8,3-吡咯烷]-1-甲酸基酯 乙基7'-氨基-6-氟-2,2',4'-三羰基-1,1',2,2',3',4'-六氢螺[吲哚-3,5'-吡喃并[2,3-d]嘧啶]-6'-羧酸酯 7H-吡喃并[2,3-d]嘧啶-7-酮 7H-吡喃并[2,3-d]嘧啶 7,8-二氢-5H-吡喃并[4,3-D]嘧啶-2-胺 5H-吡喃并[4,3-d]嘧啶 5H-吡喃并[2,3-d]嘧啶 2H-吡喃并[2,3-d]嘧啶-6-甲腈,7-氨基-1,3,4,5-四氢-5-(4-甲氧苯基)-2,4-二羰基- 2,4-二氯-7,8-二氢-5H-吡喃[4,3-d]嘧啶 1H-吡喃并[3,4-d]嘧啶 1H-吡喃并[3,2-d]嘧啶 (5S,7R,8S)-2-methylsulfanyl-5,8-dihydro-7-allyloxymethyl-5-methoxy-pyrano[3,4-d]-pyrimidin-8-ol 5-ethyl-2-[(Z)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-ethyl-2-[[1-(3-methylbutanoyl)piperidin-4-ylidene]amino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 5-butyl-2-[(E)-1-(4-cyclohexylpiperazin-1-yl)butylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione 2,3,3a,9-tetrahydro-5-iodo-2,3,3-trimethylimidazo[5,1-b][1,3]benzoxazin-1-one 2,4-dimethyl-9-methoxy-4,12b-dihydro-1H,7H-chromeno[4',3'-4,5]pyrano[2,3-d]pyrimidine-1,3(2H)-dione 5-methyl-3-{3-[(R)-2-oxo-3-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-oxazolidin-5-yl]-propyl}-1H-quinazoline-2,4-dione 7-amino-2-(benzothiazol-2-ylmethyl)-9-phenylthiazolo[4',5':6,5]pyrano[2,3-d]pyrimidine-8(7H)-one 2-[6-[(2-chlorophenyl)methyl]pyridin-2-yl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 8-amino-2-(methylthio)-5-oxo-6-(pyridin-4-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 5-(4-chlorophenyl)-1,3,8,8-tetramethyl-7,9-dihydro-5H-chromeno[2,3-d]pyrimidine-2,4,6-trione ethyl 7'-amino-2,4'-dioxo-2'-thioxo-1,1',2,2',3',4'-hexahydrospiroindole-3,5'-pyrano[2,3-d]pyrimidine-6'-carboxylate 8-amino-2-(methylthio)-5-oxo-6-(pyridin-3-yl)-5,6-dihydro-4H-pyrano[2,3-d][1,3]thiazolo[4,5-b]pyridine-7-carbonitrile 7-Amino-4-oxo-5-phenyl-2-thioxo-1,3,4,5-tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 3-(1H-benzoimidazol-2-yl)-3-butyl-5-methyl-dihydro-furan-2-one 3-(1H-benzoimidazol-2-yl)-3-(2-diethylamino-ethyl)-5-methyl-dihydro-furan-2-one 1-{4-[(1R,9S)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea (S)-6-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyridin-2(1H)-one 3-(1H-benzoimidazol-2-yl)-5-methyl-3-(3-methyl-butyl)-dihydro-furan-2-one 13-(3,4-dimethoxyphenyl)-5,5-dimethyl-2-thioxo-2,5,6,8,9,13-hexahydro-4H-pyrimido[5',4':6,7][1,8]naphthyridino[4,3,2-de]quinazoline-10,12(3a1H,11H)-dione (S)-3-allyl-8-ethyl-4,7-dioxo-2-(phenylcarbamoyl)-4,5,7,8-tetrahydro-3H-pyrano[4,3-d]pyrimidin-8-yl acetate 8-{[(2-bromo-3-methylphenyl)oxy]methyl}-1,3-dimethyl-2,3,4,6-tetrahydro-1H-pyrano[3,2-d]pyrimidine-2,4-dione 9-ethyl-6a-methyl-2-phenyl-8,9-dihydro-oxazolo[2,3-b]pyrimido[4,5-d][1,3]oxazin-5-one (S)-1-cyclobutyl-3-(4-(4-(3-methylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenyl)urea (S)-2-(4-(4-(3-ethylmorpholino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)phenylamino)pyrimidin-4(3H)-one (6aRS,10aRS)-4,6,6a,7,8,9,10,10a-octahydro-2,4,6,6-tetramethyl-1H-<2>benzopyrano<3,4-d>pyrimidine-1,3(2H)-dione 5-ethyl-2-[(E)-1-thiophen-3-ylpentylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione N3-(methyl 4-deoxy-α-L-threo-hex-4-enopyranosyluronate)-5-fluorouracil 1-{4-[(1S,9R)-3-((S)-3-methyl-morpholin-4-yl)-12-oxa-4,6-diaza-tricyclo[7.2.1.0-2,7]dodeca-2(7),3,5-trien-5-yl]-phenyl}-3-oxetan-3-yl-urea 4,5-dimethyl-12-(4-methoxyphenyl)-2-thioxo-2,4a,7,8,9,10,11,12-octahydrodipyrimido[4,5-b;4',5'-f] [1,8]naphthyridine-9,11-dione 2-[4-[2-hydroxyethyl(methyl)amino]-2-methyl-7-oxopyrimido[5,4-b][1,4]oxazin-8-yl]acetonitrile 5-ethyl-2-[(Z)-1-thiophen-2-ylethylideneamino]oxy-3H-pyrano[2,3-d]pyrimidine-4,7-dione